SCHEMBL17407642

SCHEMBL17407642

Cc1ccc(Cc2nc3c(Cc4ccccc4)[nH]c(-c4ccccc4)cn-3c2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALKBH3 Q96Q83 3/20 0.38
▸ LTB4R Q15722 1/20 0.36
▸ SMN1; SMN2 Q16637 5/20 0.36
▸ TP53 P04637 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRB2 P47870 1/20 0.36
▸ POLB P06746 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ MMP9 P14780 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ HTT P42858 3/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20841748 0.97 ALKBH3 (0.41) ALKBH3LTB4RSMN1; SMN2GABRA1GABRB2
SCHEMBL17407641 0.94 CDC7 (0.43) ALKBH3LTB4RSMN1; SMN2GABRA1GABRB2
SCHEMBL492636 0.93 LTB4R (0.41) ALKBH3LTB4RSMN1; SMN2POLBRAB9A
SCHEMBL10196888 0.93 ABCB1 (0.39) ALKBH3SMN1; SMN2GABRA1GABRB2POLB
SCHEMBL20841761 0.93 ABCB1 (0.39) ALKBH3SMN1; SMN2GABRA1GABRB2POLB
SCHEMBL24329824 0.93 ADORA3 (0.39) ALKBH3SMN1; SMN2TP53GABRA1GABRB2
SCHEMBL19206667 0.92 LTB4R (0.39) ALKBH3LTB4RRAB9AALDH1A1KDM4E
SCHEMBL13484442 0.91 ALDH1A1 (0.42) SMN1; SMN2TP53POLBRAB9ANPC1
SCHEMBL17299341 0.91 ALKBH3 (0.38) ALKBH3SMN1; SMN2TP53GABRA1GABRB2
SCHEMBL20543611 0.90 THRB (0.42) ALKBH3SMN1; SMN2TP53THRBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160002703-A1 IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002703-A1 IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES GLB1, NISCH, BOLA2; BOLA2B ALKBH3 4617/4885LTB4R 558/4885SMN1; SMN2 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback